Novartis AG Form 6-K Summary: Second Quarter 2011
Business Context and Reporting Period
This filing covers the second quarter and first half of 2011 for Novartis AG, a diversified healthcare company with leading positions in pharmaceuticals, eye care (Alcon), generics (Sandoz), vaccines, diagnostics, and consumer health. The report highlights the successful integration of the Alcon merger, completed in April 2011, and the company's strategy of innovation, growth, and productivity.
Key Financial Metrics
| Metric | Q2 2011 | Q2 2010 | H1 2011 | H1 2010 |
|---|---|---|---|---|
| Net Sales (USD bn) | 14.9 | 11.7 | 28.9 | 23.8 |
| Operating Income (USD bn) | 3.3 | 3.0 | 6.7 | 6.5 |
| Net Income (USD bn) | 2.7 | 2.4 | 5.5 | 5.4 |
| EPS (USD) | 1.13 | 1.06 | 2.33 | 2.34 |
| Core Operating Income (USD bn) | 4.2 | 3.3 | 8.2 | 7.1 |
| Core EPS (USD) | 1.48 | 1.20 | 2.88 | 2.65 |
| Free Cash Flow (USD bn) | 3.3 | 2.4 | 4.9 | 5.3 |
| Net Debt (USD bn) | 21.9 (as of June 30) | - | 21.9 (as of June 30) | 14.9 (as of Dec 31) |
Note: Sales growth in constant currencies (cc) was 19% for Q2 and 16% for H1. Core operating income margin improved to 28.4% in Q2.
Material Changes vs. Prior Period
- Revenue Growth: Net sales grew 27% in Q2 (19% cc), driven by volume growth of 8% in Pharmaceuticals and strong performance from Alcon (12% pro forma growth) and Sandoz (25% growth). Currency effects contributed 8% to Q2 sales growth.
- Profitability: Core operating income rose 29% (30% cc) in Q2, demonstrating excellent operating leverage. Core margin increased by 0.4 percentage points in USD terms (2.6 pp cc).
- Divisional Performance:
- Pharmaceuticals: Sales up 10% (2% cc). Recently launched products (e.g., Gilenya, Tasigna, Lucentis) contributed 28% of sales.
- Alcon: Pro forma sales up 12% (6% cc). Strong growth in emerging markets and ophthalmic pharmaceuticals.
- Sandoz: Sales up 25% (16% cc), driven by volume growth of 26 pp offset by price erosion of 13 pp.
- Vaccines & Diagnostics: Sales declined 47% (50% cc) primarily due to the absence of A(H1N1) pandemic flu vaccine sales from the prior year.
- Exceptional Items: Q2 operating income included a $324 million gain from the sale of Elidel, offset by impairment charges ($169 million total) and legal provisions ($150 million in Sandoz).
Guidance, Outlook, and Risks
- 2011 Outlook: Group constant currency sales growth is expected to be around the double-digit mark. Pharmaceuticals is expected to deliver low- to mid-single digit growth; Alcon mid- to high-single digit; Sandoz mid- to high-single digit.
- Margin Expectations: Management expects to improve constant currency core operating income margin while absorbing price cuts and generic competition.
- Currency Impact: If June average exchange rates prevail, the full-year impact is expected to be +5% on sales and -3% on operating income.
- Capital Structure: The Board lifted the restriction limiting dividends to 35-60% of net income. Net debt increased to $21.9 billion due to dividend payments and Alcon-related share repurchases, but the company maintains a double-A credit rating.
- Risks: Forward-looking statements are subject to risks including regulatory delays, clinical trial results, patent expirations, generic competition, and integration challenges with Alcon.
Investor Verification Checklist
- Alcon Integration: Verify the realization of synergies and the impact of integration costs on future margins.
- Patent Cliffs: Monitor the impact of generic competition on key products like Diovan and Femara.
- Regulatory Approvals: Track the status of pending filings for INC424 (myelofibrosis) and ACZ885 (gout), noting the FDA advisory panel's safety concerns regarding ACZ885.
- Vaccines Recovery: Assess the trajectory of the Vaccines & Diagnostics division post-A(H1N1) and the performance of the meningococcal franchise.
- Debt Levels: Review the trajectory of net debt reduction given the increase to $21.9 billion and the commitment to shareholder returns.